Thursday, 13 August 2020

Parexel acquires Turkish firm

02 July 2014 | News | By BioSpectrum Bureau

The business will be integrated into Parexel's clinical research services business

The business will be integrated into Parexel's clinical research services business

Singapore: Parexel, a global clinical research organization with strong base in Asia, has acquired all outstanding equity securities of Atlas Medical Services, a provider of clinical research services in Turkey, the Middle East, and North Africa.

Atlas provides services across all phases of clinical development and has therapeutic expertise in oncology, hematology, endocrinology, cardiovascular, anesthesiology, infectious diseases and central nervous system. The firm also provides clinical trial-related services from study planning and feasibility, through site selection, data management and medical writing. Atlas also provides regulatory services and can support product registration.

Atlas was founded in 2005 and has 35 employees headquartered in Istanbul, with additional offices in Ankara and Izmir. The business will be integrated into Parexel's clinical research services business.

Mr Josef von Rickenbach, chairman and ceo, Parexel stated, "The acquisition of Atlas strengthens Parexel's presence in Turkey, Middle East and North Africa. These markets are of increasing importance to our clients who are looking for market access and a broad spectrum of patient populations for clinical trials. In addition, Atlas has been a trusted business partner to Parexel for many years, and their infrastructure and staff are already aligned with our processes and operations. By fully integrating Atlas into Parexel's global operations, we will enhance our ability to help clients more quickly achieve their goals of bringing important therapies to patients not only in Turkey, the Middle East, and North Africa, but also throughout the rest of the world."

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls